RGLS - Regulus Therapeutics Enterprise Value to EBITDA Ratio
Investing in Regulus Therapeutics (RGLS) carries high risks due to a lack of sales and a dependence on scientific research outcomes, which often necessitates new equity offerings. This EV/EBITDA chart, where the value is , clearly illustrates price changes and underscores the link between financial stability and the development of RNA therapies for kidney disease. However, positive Phase 1 trial results and patent protection establish a solid foundation for expansion.
Analytical breakdowns for regulusrx.com (RGLS)
- market price and analyst price targets:
- market capitalization statistics:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Regulus Therapeutics|RGLS - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Regulus Therapeutics Inc.|RGLS - Aggregate Debt Obligations|Debts to Book Capitalization Regulus|RGLS - Long-Term Debt|Company Short-Term Debt Regulus Therapeutics|Quick Ratio regulusrx.com
- business earnings and investment ratios data:
RGLS - Net Profit|Expected Profit Regulus Therapeutics|RGLS - Market Cap to Net Income|Forward P/E Multiple Regulus Therapeutics|RGLS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Regulus|RGLS - Operating profit EBITDA|Net earnings per share for the last 12 months Regulus Therapeutics|RGLS - Earnings per share for the last four quarters|Quarterly EPS earnings growth regulusrx.com|RGLS - Expected net earnings per share growth this year|Earnings growth forecast for next year Regulus Therapeutics
Summary company analysis:Regulus Therapeutics Inc RGLS
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profitability to determine the company's resilience to debt load. By analyzing fluctuations in the EV/EBITDA level, an investor assesses the asset's ability to service obligations amidst revenue volatility. For Regulus Therapeutics (RGLS), this calculation is critical, as the dependence on microRNA drug approvals and R&D expenditures makes cash reserves the determining factor for survival.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Qiagen Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IONS: Enterprise Value to EBITDA Ratio|RGEN - EV/EBITDA Multiple|Avidity Biosciences, Inc. (RNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRSP - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio WGS|RARE: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio BEAM (Beam Therapeutics Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|Business Value to Operating Income Before Depreciation TXG|Intellia - EV/EBITDA Multiple|Company Value to EBITDA Stoke Corp|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|wavelifesciences.com - Business Value to Operating Income Before Depreciation|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|EV/EBITDA Multiple Sionna Therapeutics, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|TSHA: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple QURE (uniQure N.V.)|meiragtx.com (MGTX) - Company Value to EBITDA|RGNX: Enterprise Value to EBITDA Ratio|SLDB - EV/EBITDA Multiple|OCGN (Ocugen Corp) - Enterprise Value to EBITDA Ratio|PACB: Enterprise Value to Operating Income Before Depreciation Ratio|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|designtx.com (DSGN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RCKT|Enterprise Value to EBITDA Ratio 4DMT FDMT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|Total Company Value to Operating Income Before Depreciation Ratio Korro Bio Inc. (KRRO)|EDIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation SLN (silence-therapeutics.com)|PRQR: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Codexis CDXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sangamo|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NAUT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|Total Company Value to Operating Income Before Depreciation Ratio precisionbiosciences.com|EV/EBITDA Multiple GBIO (Generation Bio)|BOLD: Enterprise Value to Operating Income Before Depreciation|XCUR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMNN (Imunon, Inc.) - Enterprise Value to Operating Income Before Depreciation|PHIO: EV/EBITDA Multiple|Mustang Bio (MBIO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TransCode Therapeutics Inc.|BNGO: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple APDN|BLUE - Company Value to EBITDA|EV/EBITDA Multiple IPA (ImmunoPrecise Antibodies Ltd.)|Enterprise Value to EBITDA Multiple omegatherapeutics.com|OMIC: Enterprise Value to EBITDA Ratio|SYRS - EV/EBITDA Multiple|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TCON (TRACON Pharmaceuticals, Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio UBX
